We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Horizon Discovery Group Signs Agreement with Top Ten Pharma Company for Approximately $750,000

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Horizon Discovery Group Signs Agreement with Top Ten Pharma Company for Approximately $750,000"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Horizon Discovery Group plc has announced that its Horizon CombinatoRx division has been contracted by a top ten pharma company to profile a lead oncology asset. Under the terms of the agreement, Horizon CombinatoRx will be paid approximately USD $750,000 (GBP £469,000) for work to be completed within a five month period.

Horizon CombinatoRx provides its partners access to the unique cHTS platform and Chalice™ analytics software, which enable the screening and analysis of thousands of complementary drug combinations.  Combined with Horizon’s GENESIS™ (rAAV, CRISPR and ZFN) gene editing platform and X-MAN™ isogenic cell line technology, Horizon CombinatoRx offers services including novel phenotypic cell-based screens with compound siRNA, shRNA and sgRNA (for CRISPR based screening) libraries.

Horizon completed the acquisition of the CombinatoRx service business and assets from Zalicus Inc. in June 2014.

Dr Darrin M Disley, Chief Executive Officer of Horizon Discovery Group plc, commented: “We are delighted that Horizon CombinatoRx continues to gain the traction in the market we expected following the acquisition earlier this year.  This latest contract with a top ten pharma in the oncology space continues to demonstrate the value Horizon CombinatoRx can offer to support key drug discovery and development programs in cancer.”